bioRxivBiochemistryPreprint
Prolonging coagulant activity of factor Xa under hemophilic conditions by site-specific N-glycosylation of the surface-exposed autolysis loop
A. C. Bonde, J. Lund, J. J. Hansen, J. R. Winther, S. Zahn, P. Tiainen, O. H. Olsen, H. H. Petersen, J. R. Bjelke
Abstract
The regulation of Factor X (FX) is critical to maintain hemostasis. To gain insights to the regulation of the active and zymogen form of coagulation FX, we probed specific molecular interactions by introducing novel N-linked glycosylations on the surface-exposed loop spanning residues 143-150 (chymotrypsin numbering) of FX. Introduction of N-glycans in the autolysis loop of these FX variants decreased Factor VIIa (FVIIa)-mediated activation ~3-fold and prothrombin activation 2- to 10-fold presumably through steric hinderance. Prothrombin activation was, however, recovered in presence of cofactor Factor Va (FVa) despite a reduced prothrombinase assembly. The introduced N-glycans exhibited position-specific effects on the interaction with two FXa inhibitors: tissue factor pathway inhibitor (TFPI) and antithrombin (ATIII). Ki for the inhibition by full-length TFPI of these FXa variants was increased by 7- to 1150-fold, while ATIII inhibition in the presence of the heparin-analogue Fondaparinux was modestly increased by 2- to 15-fold compared to wild type. To probe the in vitro hemostatic effect of the FX variants, the thrombin generation potential in FX-depleted plasma was evaluated. When supplemented in zymogen form, the FX variants exhibited reduced thrombin generation activity relative to wild-type FX, whereas enhanced procoagulant activity was measured for activated FX variants with N-glycosylation at positions 148-150. These results indicate that residues of the surface-exposed autolysis loop and residues close by participate in FX activation, proteolytic activity and inhibition of FXa by TFPI and ATIII. In plasma-based assays, a modest decrease in FX-activation rate appeared to compensate for the collective reduction in inhibitor interactions.
- organism: human
- assay: protein structure
- research focus: host-pathogen & immune response
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Cryo-EM structures of apo human Factor XIa reveal catalytic-domain flexibility and exposure of the Factor IX-binding site
Alena I. Siutkina, Alexander Neuhaus, … Dmitrii V. Kalinin·bioRxiv·Aug 26, 2026
- Thrombin activation of the factor XI dimer is a multi-staged process for each subunit
A. Bar Barroeta, P. Albanese, … R. A. Scheltema·bioRxiv·Feb 11, 2023
- Rationally designed Gla-domainless FXa as TFPI bait in hemophilia
A. Thomas, M.-C. Dagher, … B. Polack·bioRxiv·Aug 3, 2022
- Identification of novel glycosylation events on human serum-derived Factor IX
C. L. Pegg, L. F. Zacchi, … B. L. Schulz·bioRxiv·Mar 6, 2020
- Intrinsic-like blood coagulation activity in fish: Involvement of hepatocyte growth factor activator and interspecific diversity
Shintaro Matsui, Asami Yoshida·bioRxiv·Oct 27, 2026
- Evaluation of a potential redox switch in blood coagulation tenase
K. M. Cook, D. Butera, P. J. Hogg·bioRxiv·Jan 9, 2019